 Thomas Parker
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Circulation | 20 | 2006 | 430 | 1.330 |
Why?
| | Neonatology | 3 | 2017 | 28 | 0.980 |
Why?
| | Competency-Based Education | 1 | 2024 | 79 | 0.810 |
Why?
| | Clinical Competence | 4 | 2024 | 1244 | 0.780 |
Why?
| | Nitric Oxide Synthase | 16 | 2006 | 235 | 0.760 |
Why?
| | Parental Leave | 1 | 2022 | 27 | 0.740 |
Why?
| | Sheep | 36 | 2010 | 880 | 0.690 |
Why?
| | Faculty, Medical | 1 | 2024 | 302 | 0.680 |
Why?
| | Internship and Residency | 3 | 2024 | 1257 | 0.650 |
Why?
| | Education, Medical, Graduate | 3 | 2024 | 557 | 0.650 |
Why?
| | Fetus | 19 | 2005 | 803 | 0.640 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 357 | 0.640 |
Why?
| | Nitric Oxide | 18 | 2010 | 897 | 0.570 |
Why?
| | Intensive Care, Neonatal | 1 | 2018 | 42 | 0.560 |
Why?
| | Vasodilation | 15 | 2005 | 523 | 0.520 |
Why?
| | Communication Barriers | 1 | 2018 | 124 | 0.510 |
Why?
| | Estradiol | 4 | 2001 | 533 | 0.480 |
Why?
| | Lung | 19 | 2006 | 4109 | 0.410 |
Why?
| | Parents | 2 | 2022 | 1403 | 0.410 |
Why?
| | Ductus Arteriosus | 10 | 2005 | 72 | 0.400 |
Why?
| | Pulmonary Artery | 10 | 2005 | 1134 | 0.390 |
Why?
| | Hypertension, Pulmonary | 12 | 2005 | 1980 | 0.350 |
Why?
| | Vascular Resistance | 9 | 2006 | 367 | 0.350 |
Why?
| | Nitric Oxide Synthase Type III | 9 | 2010 | 204 | 0.340 |
Why?
| | Animals, Newborn | 8 | 2005 | 902 | 0.280 |
Why?
| | Amides | 2 | 2006 | 101 | 0.270 |
Why?
| | Hemodynamics | 18 | 2006 | 1121 | 0.250 |
Why?
| | Curriculum | 1 | 2013 | 1059 | 0.240 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.220 |
Why?
| | Pediatrics | 1 | 2013 | 1114 | 0.220 |
Why?
| | Utah | 1 | 2024 | 81 | 0.210 |
Why?
| | Sulfones | 1 | 2005 | 127 | 0.210 |
Why?
| | Formative Feedback | 1 | 2024 | 31 | 0.210 |
Why?
| | Vasoconstriction | 2 | 2005 | 217 | 0.210 |
Why?
| | Fetal Growth Retardation | 5 | 2010 | 587 | 0.200 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 459 | 0.190 |
Why?
| | Endothelium, Vascular | 4 | 2006 | 965 | 0.190 |
Why?
| | Nitroarginine | 8 | 2006 | 57 | 0.180 |
Why?
| | Colorado | 2 | 2024 | 4564 | 0.170 |
Why?
| | Focus Groups | 1 | 2024 | 573 | 0.170 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 48 | 0.170 |
Why?
| | Educational Measurement | 1 | 2024 | 326 | 0.170 |
Why?
| | Oxygen | 7 | 2004 | 995 | 0.160 |
Why?
| | Pregnancy | 17 | 2010 | 7190 | 0.150 |
Why?
| | Infant, Newborn | 11 | 2018 | 6429 | 0.150 |
Why?
| | Blood Vessels | 1 | 2000 | 171 | 0.140 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 457 | 0.140 |
Why?
| | Animals | 37 | 2010 | 38058 | 0.130 |
Why?
| | Bronchodilator Agents | 3 | 2007 | 182 | 0.130 |
Why?
| | Gestational Age | 9 | 2010 | 975 | 0.130 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2003 | 410 | 0.130 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6048 | 0.130 |
Why?
| | Placenta | 5 | 2010 | 780 | 0.130 |
Why?
| | Enzyme Inhibitors | 6 | 2006 | 824 | 0.120 |
Why?
| | Epoprostenol | 1 | 1997 | 131 | 0.120 |
Why?
| | Physician's Role | 1 | 2017 | 218 | 0.120 |
Why?
| | Delphi Technique | 1 | 2017 | 329 | 0.110 |
Why?
| | High-Frequency Ventilation | 3 | 2000 | 45 | 0.110 |
Why?
| | Language | 1 | 2018 | 321 | 0.110 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 279 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 1997 | 113 | 0.110 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2007 | 138 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2005 | 557 | 0.110 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2005 | 452 | 0.110 |
Why?
| | Blotting, Western | 6 | 2007 | 1187 | 0.110 |
Why?
| | Administration, Inhalation | 9 | 2007 | 574 | 0.110 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 675 | 0.110 |
Why?
| | Antihypertensive Agents | 2 | 2000 | 510 | 0.100 |
Why?
| | Physician Executives | 1 | 2013 | 27 | 0.100 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 64 | 0.090 |
Why?
| | Lymphokines | 2 | 2002 | 130 | 0.090 |
Why?
| | Humans | 18 | 2024 | 144759 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 5 | 2005 | 119 | 0.090 |
Why?
| | Endothelin-1 | 4 | 2000 | 184 | 0.090 |
Why?
| | United States | 2 | 2022 | 15966 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2002 | 381 | 0.080 |
Why?
| | Data Collection | 1 | 2013 | 633 | 0.080 |
Why?
| | Education | 1 | 2011 | 104 | 0.080 |
Why?
| | Disease Models, Animal | 9 | 2010 | 4557 | 0.080 |
Why?
| | Endothelin Receptor Antagonists | 3 | 2000 | 62 | 0.080 |
Why?
| | RNA, Messenger | 4 | 2010 | 2832 | 0.080 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 173 | 0.070 |
Why?
| | Female | 19 | 2018 | 78271 | 0.070 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 1999 | 106 | 0.070 |
Why?
| | Umbilical Arteries | 2 | 2006 | 52 | 0.070 |
Why?
| | Hyaline Membrane Disease | 2 | 1998 | 20 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 436 | 0.070 |
Why?
| | Fluorocarbons | 2 | 1999 | 143 | 0.060 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 118 | 0.060 |
Why?
| | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2006 | 28 | 0.060 |
Why?
| | Prospective Studies | 1 | 2018 | 7990 | 0.060 |
Why?
| | Ligation | 3 | 2002 | 92 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2006 | 83 | 0.060 |
Why?
| | Vasodilator Agents | 3 | 2003 | 331 | 0.060 |
Why?
| | Fetal Diseases | 2 | 2004 | 191 | 0.060 |
Why?
| | Uterus | 2 | 2006 | 226 | 0.060 |
Why?
| | Immunohistochemistry | 4 | 2006 | 1716 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1185 | 0.060 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 74 | 0.050 |
Why?
| | Positive-Pressure Respiration | 2 | 2003 | 112 | 0.050 |
Why?
| | Regional Blood Flow | 3 | 2006 | 514 | 0.050 |
Why?
| | Respiration Disorders | 1 | 2005 | 77 | 0.050 |
Why?
| | Endothelin B Receptor Antagonists | 1 | 2004 | 12 | 0.050 |
Why?
| | Hypertension | 2 | 2005 | 1263 | 0.050 |
Why?
| | Cyclic GMP | 2 | 2001 | 92 | 0.050 |
Why?
| | Drug Combinations | 1 | 2005 | 390 | 0.050 |
Why?
| | Receptors, Endothelin | 2 | 2000 | 50 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2006 | 2027 | 0.050 |
Why?
| | Isoenzymes | 2 | 2001 | 299 | 0.050 |
Why?
| | Vasomotor System | 2 | 2002 | 46 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2005 | 301 | 0.050 |
Why?
| | Embryonic and Fetal Development | 2 | 2000 | 93 | 0.050 |
Why?
| | Blotting, Northern | 2 | 2000 | 204 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 286 | 0.050 |
Why?
| | Hernia, Diaphragmatic | 1 | 2003 | 67 | 0.050 |
Why?
| | Piperidines | 2 | 2004 | 217 | 0.050 |
Why?
| | Oligopeptides | 2 | 2004 | 269 | 0.050 |
Why?
| | Child | 1 | 2022 | 22633 | 0.050 |
Why?
| | Fatal Outcome | 2 | 2007 | 307 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2004 | 383 | 0.040 |
Why?
| | Respiration, Artificial | 4 | 2001 | 708 | 0.040 |
Why?
| | Pyridines | 1 | 2006 | 605 | 0.040 |
Why?
| | Blood Gas Analysis | 2 | 2000 | 83 | 0.040 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 26 | 0.040 |
Why?
| | Young Adult | 1 | 2018 | 14105 | 0.040 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.040 |
Why?
| | Prostaglandins | 1 | 2001 | 94 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 66 | 0.040 |
Why?
| | Recombinant Proteins | 4 | 2005 | 1370 | 0.040 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 83 | 0.040 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 165 | 0.040 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2003 | 182 | 0.040 |
Why?
| | Organ Specificity | 1 | 2001 | 312 | 0.040 |
Why?
| | Plethysmography | 1 | 2001 | 108 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2001 | 66 | 0.040 |
Why?
| | Placental Insufficiency | 1 | 2002 | 125 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 162 | 0.040 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2003 | 219 | 0.040 |
Why?
| | Endothelins | 1 | 2000 | 63 | 0.040 |
Why?
| | Physical Stimulation | 1 | 2000 | 68 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2006 | 969 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2001 | 779 | 0.040 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2000 | 150 | 0.040 |
Why?
| | Muscle, Smooth | 1 | 2000 | 153 | 0.040 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 63 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 47 | 0.040 |
Why?
| | Receptor, Endothelin B | 3 | 2004 | 48 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2010 | 905 | 0.030 |
Why?
| | Medical Records | 1 | 1998 | 187 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1997 | 106 | 0.030 |
Why?
| | Biological Products | 1 | 2000 | 252 | 0.030 |
Why?
| | Capillary Permeability | 1 | 1997 | 134 | 0.030 |
Why?
| | Signal Transduction | 2 | 2010 | 5226 | 0.030 |
Why?
| | Adult | 2 | 2018 | 40449 | 0.030 |
Why?
| | Male | 4 | 2018 | 72315 | 0.030 |
Why?
| | Blood Pressure | 4 | 2005 | 1769 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 1997 | 105 | 0.030 |
Why?
| | Pulsatile Flow | 2 | 2006 | 55 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1998 | 1306 | 0.030 |
Why?
| | Acetylcholine | 3 | 2001 | 204 | 0.030 |
Why?
| | Neutrophils | 2 | 1999 | 1134 | 0.030 |
Why?
| | Echocardiography | 1 | 1997 | 652 | 0.030 |
Why?
| | Stress, Mechanical | 3 | 2001 | 494 | 0.020 |
Why?
| | Pregnancy Complications, Cardiovascular | 2 | 2004 | 83 | 0.020 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 80 | 0.020 |
Why?
| | Pilot Projects | 1 | 1998 | 1886 | 0.020 |
Why?
| | Inflammation | 1 | 2003 | 2878 | 0.020 |
Why?
| | Liability, Legal | 1 | 2011 | 43 | 0.020 |
Why?
| | Medical Staff, Hospital | 1 | 2011 | 80 | 0.020 |
Why?
| | Hypoxia | 1 | 1998 | 1199 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2001 | 162 | 0.020 |
Why?
| | Reference Values | 2 | 2002 | 797 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2010 | 91 | 0.020 |
Why?
| | Uterine Artery | 1 | 2010 | 75 | 0.020 |
Why?
| | Hyperthermia, Induced | 1 | 2010 | 121 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 38 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 47 | 0.020 |
Why?
| | Carbon Dioxide | 2 | 2000 | 242 | 0.020 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 4 | 0.020 |
Why?
| | Fetal Weight | 1 | 2007 | 54 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 269 | 0.020 |
Why?
| | Treatment Failure | 1 | 2007 | 365 | 0.020 |
Why?
| | Peptides, Cyclic | 2 | 1998 | 275 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 983 | 0.010 |
Why?
| | Lung Compliance | 1 | 2005 | 42 | 0.010 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2005 | 67 | 0.010 |
Why?
| | Radiography | 1 | 2007 | 844 | 0.010 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2005 | 31 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 824 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2003 | 17066 | 0.010 |
Why?
| | Down-Regulation | 1 | 2006 | 627 | 0.010 |
Why?
| | Parturition | 1 | 2004 | 69 | 0.010 |
Why?
| | Chronic Disease | 2 | 2002 | 1813 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 851 | 0.010 |
Why?
| | Trachea | 1 | 2005 | 261 | 0.010 |
Why?
| | Ventilator Weaning | 1 | 2003 | 39 | 0.010 |
Why?
| | Treatment Outcome | 1 | 1998 | 11679 | 0.010 |
Why?
| | Chromones | 1 | 2002 | 42 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2004 | 413 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 109 | 0.010 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 56 | 0.010 |
Why?
| | Morpholines | 1 | 2002 | 128 | 0.010 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2002 | 26 | 0.010 |
Why?
| | Placentation | 1 | 2002 | 53 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 27 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 9 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 20 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 151 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2001 | 81 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 138 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 43 | 0.010 |
Why?
| | Guanidines | 1 | 2001 | 41 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 15 | 0.010 |
Why?
| | Time Factors | 2 | 2003 | 7173 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2002 | 766 | 0.010 |
Why?
| | Morphogenesis | 1 | 2002 | 173 | 0.010 |
Why?
| | Pressure | 1 | 2002 | 225 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 154 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 165 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2002 | 194 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2002 | 380 | 0.010 |
Why?
| | Calibration | 1 | 2001 | 151 | 0.010 |
Why?
| | Body Weight | 1 | 2004 | 976 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 398 | 0.010 |
Why?
| | Respiration | 1 | 2001 | 206 | 0.010 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2000 | 30 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2947 | 0.010 |
Why?
| | Pulmonary Surfactants | 1 | 2000 | 102 | 0.010 |
Why?
| | Trophoblasts | 1 | 2002 | 216 | 0.010 |
Why?
| | Indazoles | 1 | 2000 | 80 | 0.010 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.010 |
Why?
| | Protein Precursors | 1 | 2000 | 137 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 4 | 0.010 |
Why?
| | Tetraethylammonium | 1 | 1999 | 16 | 0.010 |
Why?
| | Heart Rate, Fetal | 1 | 1999 | 31 | 0.010 |
Why?
| | 4-Aminopyridine | 1 | 1999 | 30 | 0.010 |
Why?
| | Quality of Life | 1 | 2011 | 3185 | 0.010 |
Why?
| | Enzyme Induction | 1 | 1997 | 88 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1997 | 151 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 316 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 194 | 0.010 |
Why?
| | Congenital Abnormalities | 1 | 1997 | 104 | 0.010 |
Why?
| | Incidence | 1 | 2003 | 2879 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 174 | 0.010 |
Why?
| | Algorithms | 1 | 2000 | 1837 | 0.010 |
Why?
|
|
Parker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|